Oral versus parenteral administration of methotrexate for the treatment of active RA: Commentary

Nature Clinical Practice Rheumatology

Volumn 4, Issue 7, 2008, Pages 342-343

  Todd, Derrick J ^a   Weinblatt, Michael E ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

METHOTREXATE; PLACEBO;

ARTHRALGIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG SAFETY; HUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; SHORT SURVEY; SYMPTOM; UNSPECIFIED SIDE EFFECT;

EID: 47149091548     PISSN: 17458382     EISSN: 17458390     Source Type: Journal    
DOI: 10.1038/ncprheum0827     Document Type: Short Survey

References (4)

1. Sosin M and Handa S (2003) Low dose methotrexate and bone marrow suppression. BMJ 326: 266-267
2. Brooks PJ et al. (1990) Pharmacokinetics of methotrexate administered by intramuscular and subcutaneous injections in patients with rheumatoid arthritis. Arthritis Rheum 33: 91-94
3. Jundt JW et al. (1993) A comparison of low dose methotrexate bioavailability: Oral solution, oral tablet, subcutaneous and intramuscular dosing. J Rheumatol 20: 1845-1849
4. Hoekstra M et al. (2004) Bioavailability of higher dose methotrexate comparing oral and subcutaneous administration in patients with rheumatoid arthritis. J Rheumatol 31: 645-648